Determinants of medication incident reporting, recovery, and learning in community pharmacies: a conceptual model

Todd A Boyle1, Thomas Mahaffey, Neil J Mackinnon

  • 1Schwartz School of Business and Information Systems, St. Francis Xavier University, Antigonish, Nova Scotia B2G 2W5, Canada. tboyle@stfx.ca

Abstract

Insights

Underreporting of medication incidents (MIs) in community pharmacies is high. Improving reporting, service recovery, and learning requires addressing factors like self-efficacy, organizational culture, and management support.

Area of Science:

  • Pharmacy Practice
  • Patient Safety
  • Organizational Behavior

Background:

  • Medication incidents (MIs) are frequently underreported in community pharmacies.
  • MIs offer crucial learning opportunities for improving patient safety and pharmacy operations.
  • Effective reporting and discussion are essential for learning from MIs.

Purpose of the Study:

  • To propose a model of factors influencing medication incident (MI) reporting, service recovery, and organizational learning in Canadian community pharmacies.
  • To identify key elements that impact the reporting process and subsequent learning from MIs.

Main Methods:

  • A conceptual model was developed based on literature synthesis and a pilot study in Nova Scotia community pharmacies.
  • A pilot study surveyed pharmacy staff (management, pharmacists, technicians) on current and desired MI reporting processes.
  • Structural Equation Modeling (SEM) was used to analyze survey data and propose the final model.

Main Results:

  • Factors influencing complete MI reporting include self-efficacy, process capability and support, organizational culture, management support, and regulatory authority.
  • Complete MI reporting is a precursor to effective service recovery and organizational learning from MIs.

Conclusions:

  • The proposed model can guide pharmacy managers in making informed decisions to improve MI reporting.
  • Identifying risk factors for low reporting allows regulators to target interventions and focus on preventative education.
  • Enhancing MI reporting, recovery, and learning is vital for continuous improvement in community pharmacy practice.

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...